Posté sur un forum peu populaire ici, mais très intéressant.
Copié et collé ici car disparait vite là-bas...
Pfizer, Bausch and Lomb to co-promote opthalmic products
Singapore, Mar 4, 2009: Pfizer and Bausch and Lomb are to co-promote their companies' prescription ophthalmic pharmaceuticals in the US.
The agreement will allow both companies to greatly increase the level of eye care industry support for these important medications that treat serious ophthalmic conditions.
The five-year agreement includes Pfizer's Xalatan (latanoprost ophthalmic solution) and Bausch & Lomb's Alrex (loteprednol etabonate ophthalmic suspension 0.2%), Lotemax (loteprednol etabonate ophthalmic suspension 0.5%) and Zylet (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension). The co-promotion agreement also will apply to Bausch & Lomb's investigational anti-infective eye drop, besifloxacin ophthalmic suspension, 0.6%, which is currently under review by the Food and Drug Administration.
A prepared company release said, as part of the agreement, both the Pfizer and Bausch & Lomb sales forces, subject to FDA approval, will promote Xalatan, Alrex, Lotemax, Zylet and besifloxacin.
"Ophthalmic disorders cause significant disability in the United States. This agreement with Bausch & Lomb combines our portfolios and further demonstrates our commitment to provide prescription medications that can benefit people living with serious eye conditions," said Olivier Brandicourt, president and general manager, Pfizer's Specialty Care business unit.
"Working in collaboration, our US sales organizations will now represent one of the broadest product offerings in the US ophthalmic market," said Flemming Ornskov, corporate vice president and global president, Pharmaceuticals, Bausch & Lomb. "We'll be able to reach considerably more eye care practitioners, and in turn, better attend to the needs of millions of patients every year."